« Return to News | Study Conduct

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009 07:19 AM

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

For phase II to IV clinical trials launched in Q2, 12,338 patients were enrolled—nearly the same as the 12,000 enrolled in the same quarter last year.

Clinical trials conducted in Russia were conducted by sponsor companies from 16 countries, with the most being initiated by Russian companies, followed by companies based in the U.S., Switzerland, Germany, UK and Japan and others.

Seventy-five percent of the studies in Q2 2009 were conducted in the following six therapeutic areas: cardiovascular, oncology, endocrinology, respiratory, infectious diseases and neurology.

The top five sponsor companies initiating the most studies in Russia during Q2 were, in order: Novartis, Pfizer, Bristol-Myers Squibb, Eli Lilly and Merck.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.